ClearPoint Neuro (CLPT) Company Report

ClearPoint Neuro reported total revenue of $8.9 million for the third quarter ended September 30, 2025, representing a 9% year-over-year increase compared to the same period in 2024.
The company reaffirmed its full-year 2025 revenue forecast, narrowing the expected range to between $36.0 million and $38.0 million.
ClearPoint Neuro announced a signed agreement for the acquisition of IRRAS Holdings, Inc., and expects the total 2026 combined revenue for the two companies to be in the range of $54.0 million to $60.0 million.
As of September 30, 2025, the company had cash and cash equivalents totaling $38.2 million.
Key operational highlights include receiving FDA 510(k) clearance for its PRISM Laser Therapy System, expanding compatibility with 1.5T MRI guidance, and the completion of its new ClearPoint Advanced Laboratories (CAL) facility, which became operational in early Q4 2025.

Nov 6, 2025, 9:57 PM

ClearPoint Neuro Announces Agreement to Acquire IRRAS Holdings, Inc.

CLPT

M&A

New Projects/Investments

Guidance Update

ClearPoint Neuro, Inc. entered into an Agreement and Plan of Merger and Reorganization with IRRAS Holdings, Inc. on November 6, 2025.
The merger consideration includes $5,000,000 in cash and 1,325,000 shares of Company common stock.
The acquisition is expected to expand ClearPoint Neuro's drug delivery portfolio, add new indications, and provide access to a $0.5 billion existing global market opportunity for the treatment of intracranial bleeding.
IRRAS Holdings, Inc. had an estimated $9.0 million revenue run-rate in the first 9 months of 2025, and the total 2026 combined revenue for both companies is expected to be in the range of $54.0 to $60.0 million.
The closing of the merger is subject to conditions, including approval by IRRAS shareholders, and is expected to be completed in the fourth quarter of 2025.

Nov 6, 2025, 9:52 PM

ClearPoint Neuro Develops Robotic Neuro-Navigation System

CLPT

Product Launch

New Projects/Investments

ClearPoint Neuro has developed a proprietary Robotic Neuro-Navigation System that integrates its navigation software with the KUKA LBR Med Robotic Arm, designed for all minimally invasive cranial surgeries.
This system aims to enhance neuro drug delivery and assist partners in commercializing new therapies, with a prototype demonstration planned at the 75th Annual Congress of Neurological Surgeons in Los Angeles.
The company recently secured $110 million in financing to support its general corporate efforts, reflecting strong investor confidence.
ClearPoint plans to commercialize this system alongside emerging cell and gene therapies under expedited FDA review, viewing robotics as integral to the future of neurosurgery.

Oct 2, 2025, 1:37 AM

ClearPoint Neuro Inc. Outlines Growth Strategy and Market Opportunity

CLPT

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

ClearPoint Neuro Inc. enables cell, gene, and device therapies by offering precise navigation to the brain and spine, utilizing a unique platform that includes clinical products and drug development services.
The company's current portfolio provides access to an estimated $500 million market opportunity today, with a potential to reach a $10 billion market diversified across 60+ partners and 20+ indications.
One partner has received FDA approval for Kebilidi, a neuro gene therapy co-labeled with ClearPoint, and the SmartFlow Neuro Cannula is the only FDA authorized device for its administration. Additionally, seven partners have programs selected for expedited FDA review.
From 2025-2027, ClearPoint Neuro plans to grow into the estimated $500 million market, activate 150 customers, launch its first commercial cell and gene therapy, and achieve operational cash breakeven.

Aug 12, 2025, 8:00 PM

ClearPoint Neuro Reports Record Q2 2025 Revenue and Secures Significant Financing

CLPT

Earnings

Guidance Update

Debt Issuance

ClearPoint Neuro, Inc. reported record quarterly revenue of $9.2 million for the second quarter ended June 30, 2025, representing a 17% year-over-year increase compared to the second quarter of 2024.
The company secured a substantial cash infusion, including $30.0 million in gross proceeds from a note financing arrangement and an additional $3.5 million from a stock purchase agreement with Oberland Capital Management.
As of June 30, 2025, ClearPoint Neuro had cash and cash equivalents totaling $41.5 million.
ClearPoint Neuro reaffirmed its full year 2025 revenue outlook to be between $36.0 million and $41.0 million.

Aug 12, 2025, 12:00 AM

ClearPoint Neuro 8-K: Approval of Key Corporate Actions and Compensation Plans

CLPT

Proxy Vote Outcomes

Executive Compensation

Auditor Change

Annual Meeting held on May 21, 2025: Stockholders approved several key proposals, including the election of eight directors to serve until the 2026 meeting.
Auditor ratification: The appointment of Cherry Bekaert LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved.
Executive compensation matters: Advisory votes on executive compensation and approval of both the Employee Stock Purchase Plan and the Sixth Amended Incentive Compensation Plan were confirmed.

May 23, 2025, 12:00 AM

ClearPoint Neuro Reports Q1 2025 Results and Strategic Initiatives

CLPT

Earnings

Product Launch

Debt Issuance

Q1 2025 revenue reached $8.5M, marking an 11% year-over-year increase with Neurosurgery Navigation up 70% to $3.3M, Biologics and Drug Delivery increasing 9% to $4.7M, and Capital Equipment revenue declining 63% to $0.5M; gross margin improved to 60%.
The company reported strategic progress with the launch of 3.0 navigation software and the full market rollout of its PRISM laser therapy system, contributing to a significant boost in its single-use consumables segment.
ClearPoint Neuro secured foundational funding from Oberland Capital, including a new credit facility and equity investment, to support accelerated hiring, expanded preclinical capacity, and progress towards GLP certification.